Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
72.40    0.90 (1.26%)
Bid:
72.60
Ask:
72.80
Spread: 0.20 (0.275%)
Market Cap: £692.93m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

Trading Statement

29 Jul 2021 07:00

RNS Number : 8142G
Dr. Martens PLC
29 July 2021
 

 

29 July 2021

Dr. Martens plc

Trading statement for the three months ended 30 June 2021

A STRONG FIRST QUARTER

"I am very pleased with the performance across our business in the first quarter of our new financial year. We achieved continued growth in ecommerce against a triple-digit growth rate last year and the reopening of our own-stores drove a strong retail recovery through the period. In addition, we saw a return to more normalised wholesale shipments over the period. The first quarter of the year is always our smallest period, being the end of the Spring/Summer season. Our larger Autumn/Winter season begins from Q2 and our performance to date gives us confidence for the remainder of the year. We will continue to take a long-term custodian mindset, investing into our business and making decisions to drive the brand for the decades to come." Kenny Wilson, Chief Executive Officer

 

Group highlights:

· Q1 Group revenue £147.3m, up 52% year on year (64% on a constant currency basis). This performance was against a Covid-19 impacted comparative figure, with revenues in the same quarter last year down 14%. On a two-year basis (Q1 FY22 compared to Q1 FY20), revenue was up 31% (40% constant currency). Q1 is typically the smallest period, being the end of the Spring/Summer season.

· By channel, we saw an encouraging recovery of retail, good growth in ecommerce against a very strong comparative and a strong wholesale performance as order patterns normalised.

· All three regions saw good growth, although the Americas was a standout, recording triple-digit revenue growth.

 

Channel performance

Throughout Q1 FY22, all US stores were open, UK stores opened from mid-April, and Continental Europe stores opened steadily through May and June. Japan remains the most impacted, with stores operating with varying capacity restrictions and a few locations remaining closed. This compares with Q1 last year, where the vast majority of our own stores globally were closed or subject to significant Covid-19 restrictions, which materially impacted retail revenues. This significantly altered picture has resulted in Q1 FY22 retail revenue more than tripling year-on-year. The performance of our stores improved as the quarter progressed, particularly those in the US and provincial UK. On a two-year basis (Q1 FY22 compared to Q1 FY20) performance was as expected, with retail revenue down 6% for the quarter as a whole and positive in the month of June.

In Q1 FY22, we achieved strong ecommerce revenue growth of 11% (19% on a constant currency basis). This was against a very high comparative with ecommerce growth in Q1 FY21 up triple-digit, given the widespread store closures at that time. On a two-year basis (Q1 FY22 compared to Q1 FY20), ecommerce revenue is up 155% (166% in constant currency terms).

We saw a very strong performance in our wholesale business in Q1 FY22, as customers normalised shipment timings back towards Q1. As a result, wholesale revenue is up 50% year-on-year (up 64% constant currency), with particularly strong shipments in Americas. This performance is against a weak comparative, as last year a large proportion of wholesale customers rescheduled orders into Q2 given the significant uncertainty at that time. On a two-year basis (Q1 FY22 compared to Q1 FY20), wholesale revenue is up 23% (30% in constant currency terms). Given the rescheduling of orders in FY21, we face a stronger comparative in Q2 and therefore expect wholesale sales growth to moderate.

Regional performance

The strongest regional performance was seen in Americas, with revenue up 106% (132% constant currency). This was predominantly driven by wholesale, with both a normalisation of shipments compared to the prior year and strong underlying growth. We also saw a good recovery in retail and continued ecommerce growth against a tough comparative.

EMEA delivered 30% revenue growth (36% constant currency). We saw an encouraging retail recovery as stores reopened, continued ecommerce growth against a very strong comparative, and good wholesale performance.

APAC saw revenues up 17% (30% constant currency), with good growth across all channels. The largest market in APAC is Japan, which continues to see significant Covid-19 restrictions in retail, albeit to a lower extent than last year.

Outlook

Trading in Q1 was slightly ahead of our expectations, with a strong end to the period. Q1 is by far the smallest quarter however, and in Q2 we face a much stronger comparative. We anticipate that the pattern of trading through the year will be non-linear and, like many others across the industry, we are experiencing inbound shipping delays and other operational challenges due to Covid-19. Despite these, we remain confident in the delivery of our guidance for FY22 and over the medium-term.

 

Enquiries

Investors and analysts

Bethany Barnes, Director of Investor Relations +44 7825 187465 bethany.barnes@drmartens.com

Media

Finsbury Glover HeringRollo Head, James Leviton +44 20 7251 3801

Gill Hammond, Director of Communications +44 7384 214248

 

 

FY21 Quarterly performance

The prior year quarterly revenue performance was as follows:

FY21

Q1

Q2

Q3

Q4

Group revenue (£m)

97.0

221.2

275.6

179.2

% yoy change (reported)

(14%)

42%

9%

19%

% yoy change (constant currency)

(14%)

43%

9%

23%

 

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage and, six decades later, "Docs" or "DMs" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. 

 

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and is a constituent of the FTSE 250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTDKFBKABKDFOB
Date   Source Headline
12th Jul 20233:59 pmRNSDirector/PDMR Shareholding
11th Jul 20231:59 pmRNSHolding(s) in Company
4th Jul 20239:12 amRNSTotal Voting Rights
4th Jul 20239:00 amRNSDirector/PDMR Shareholding
13th Jun 20231:09 pmRNSDirector/PDMR Shareholding
13th Jun 20239:00 amRNSAnnual Financial Report
7th Jun 20234:37 pmRNSNotification of transaction of PCA of PDMR
5th Jun 20234:49 pmRNSDirector/PDMR Shareholding
5th Jun 20233:00 pmRNSDirector/PDMR Shareholding
1st Jun 202312:03 pmRNSBlock listing Interim Review
1st Jun 202311:00 amRNSTotal Voting Rights
1st Jun 20237:00 amRNSFinal Results
17th May 202311:30 amRNSDirector/PDMR Shareholding
2nd May 20233:12 pmRNSTotal Voting Rights
17th Apr 20237:00 amRNSDirector/PDMR Shareholding
14th Apr 20237:01 amRNSCFO retirement
14th Apr 20237:00 amRNSTrading Statement
3rd Apr 20232:54 pmRNSTotal Voting Rights
24th Mar 20237:00 amRNSDirectorate Change
14th Mar 20235:09 pmRNSReplacement Director/PDMR Shareholding
14th Mar 20233:19 pmRNSDirector/PDMR Shareholding
1st Mar 20234:17 pmRNSTotal Voting Rights
15th Feb 20232:16 pmRNSDirector/PDMR Shareholding
6th Feb 20235:30 pmRNSDirector/PDMR Shareholding
1st Feb 202312:12 pmRNSTotal Voting Rights
19th Jan 20237:00 amRNSTrading Statement
13th Jan 20232:11 pmRNSDirector/PDMR Shareholding
3rd Jan 20233:36 pmRNSTotal Voting Rights
14th Dec 20221:35 pmRNSDirector/PDMR Shareholding
1st Dec 20228:38 amRNSTotal Voting Rights
30th Nov 202210:02 amRNSDirector/PDMR Shareholding
24th Nov 20227:00 amRNSHalf-year Report
15th Nov 20223:54 pmRNSBlock listing Interim Review
15th Nov 20223:44 pmRNSDirector/PDMR Shareholding
1st Nov 20227:00 amRNSTotal Voting Rights
1st Sep 20227:00 amRNSTotal Voting Rights
23rd Aug 20222:38 pmRNSDirector/PDMR Shareholding
1st Aug 202211:51 amRNSTotal Voting Rights
14th Jul 202212:33 pmRNSResult of AGM
14th Jul 20227:00 amRNSTrading Statement
6th Jul 20227:00 amRNSConversion Markets - teach-in event
29th Jun 20228:13 amRNSDirector Declaration
16th Jun 202212:16 pmRNSDirector/PDMR Shareholding
14th Jun 20229:00 amRNSAnnual Financial Report
1st Jun 20227:00 amRNSFinal Results
27th Apr 20228:57 amRNSDirector Declaration
1st Apr 20223:18 pmRNSTotal Voting Rights
1st Apr 20222:01 pmRNSBlock listing Interim Review
30th Mar 20227:00 amRNSBlock Listing Application
22nd Mar 20227:43 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.